Interleukins were first described as a group of signalling polypeptides, controlling the activity of lymphoid and haemopoietic cells, (O'Garra, 1989a,b) but individual members have now been shown to stimulate other cell types such as keratinocytes, chondrocytes, fibroblasts (IL-l) and glial cells of the nervous system (IL-2) (Durum et al., 1985; Benveniste & Merrill, 1986) . In addition interleukins -1 and -6 may inhibit the growth of breast cancer cells (Gafney & Tsai, 1986) .
Interleukin-4 (IL-4) was initially characterized as a B-cell growth factor, (Howard et al., 1982) but it has also been shown to exert its effects on T-lymphocytes, granulocytes, macrophages and some epithelial cell lines (O'Hara & Paul, 1987; Park et al., 1987; Fernandez-Botran et al., 1986; Mosmann et al., 1986) . It may promote or suppress the maturation of haemopoietic cells, as progenitor cells respond differently to IL-4, at different stages of maturation (Rennick et al., 1987) . Direct effects of inhibition or stimulation have been reported on melanoma cell lines (Mortarini et al., 1990) .
The capacity of IL-4 to increase the expression of secretory component, the epithelial receptor for polymeric Ig, on a colonic adenocarcinoma cell line, extends the list of effects of IL-4 and suggests the presence of IL-4 receptors on epithelial cells (Phillips et al., 1990) .
Recently it has been shown in murine tumours that IL-4 displays strong anti-tumour activity in vivo. It is proposed that localised elaboration of IL-4 (and other lymphokines) as a normal host response to a putative tumour antigen could initiate a cascade of events involving the activation of inflammatory cells and humoral mediators, leading to the destruction of the tumour cells (Tepper et al., 1989) . Antitumour effect was reversed by anti-IL-4 antibody. IL-4 can also enhance similar effects shown by IL-lb, IL-2 and interferon gamma (Forni et al., 1989) .
In view of the demonstration of IL-4 receptors on epithelial cell lines and IL-4 effects on cell lines, it would be of value to ascertain whether IL-4 plays any role in the development of progression of human cancers, particularly the commonest epithelial tumours.
A preliminary study analysed the expression of IL-4 receptors on a small number of malignant tumours including one case of colon cancer and their normal counterparts. They found that IL-4R molecules are upregulated in tumours of epithelial origin and that the antibody used, (MR6) is effective as an in vivo tumour imaging agent (Al Jabaari et al., 1989) .
The present study was undertaken to provide a detailed analysis of the distribution of IL4 receptors using a recently produced monoclonal antibody (MR6) which recognizes an antigen constantly associated with the receptor (De Maagol et al., 1985) . These results have been compared with labelling for EGFR in the same series as a control and since there is already detailed information about the distribution and role of EGFR in other epithelial neoplasms (Liberman et al., 1984; Berger et al., 1987; Gullick et al., 1986; Veale et al., 1989; Perez et al., 1984) .
Materials and methods

Tissues
Representative samples of tumour specimens were collected at resection from 44 patients with primary colon cancer and one with an anal squamous cell carcinoma. Non-neoplastic colonic tissue was also separately sampled, at least 5 cm from the edge of the tumour. Twenty colonic polyps (metaplastic: five, tubular: nine, villous: six) were also obtained, two by colonoscopic biopsy and 18 as resection specimens.
All the above tissues were snap frozen in liquid nitrogen and stored at -70°C. Histological diagnosis and evaluation of the differentiation and staging were assessed by light microscopy before immunohistochemical staining.
Antibodies
The primary antibodies used are summarised below.
Antibody MR6 The monoclonal antibody MR6 was raised against an extract of thymic tissue and shown to react strongly with thymic cortical epithelial cells. By Western blotting MR6 detects a single polypeptide of 200 kD which is rapidly cleaved to 145 kD by proteolytic enzymes. This latter is known to be the approximate molecular weight of one of the four polypeptide chains associated with the IL4 receptor. Flow cytometric and immunohistochemical studies showed the antigen to be present also on T and B lymphocytes, cells of myeloid lineage and some renal epithelium. Recent experiments strongly suggest that MR6 binds to the IL4 receptor complex by demonstrating that MR6 inihibits IL4 induced T cell proliferation and completely abrogates the IL4 production of specific antigen induced IgE by B cell populations. MR6 does not however block binding of IL4 to its receptor, which indicates that it recognises a molecule closely associated with the three chains of the IL4-R but which does not form the ligand binding component of the receptor.
The evidence that MR6 is a reliable marker of IL-4 receptor has been summarised in a previous paper; (Tungekar et al., 1991) full details of its characteristics have been described elsewhere (De Maagol et al., 1985; Larche et al., 1988a , Larche et al., 1988b .
Antibody EGFRI Monoclonal antibody EGFR1 was produced using cells of the epidermoid carcinoma cell line A431 as immunogen. EGFR1 recognises an antigen of 175,000 mwt which can be specifically cross linked to EGF and exhibits an EGF-stimulated protein kinase activity (Waterfield et al., 1982) .
Antibody Ki67 All carcinomas, polyps and normal colonic tissues were also stained with Ki67, (Gerdes et al., 1983) a monoclonal antibody against a nuclear proliferation-associated antigen, to check for viability and antigenic preservation in the tumour cells at the time of resection.
Immunocytochemistry The antibodies mentioned above were detected by means of the alkaline phosphatase anti-alkaline phosphatase (APAAP) method as described previously (Cordell et al., 1984) . Briefly 5-81aM acetone fixed sections were incubated in hybridoma supernatant at room temperature for 
Results
Antibody MR6
The main results of this study are summarized in Tables I, II and III. Positive immunoreactivity for IL-4 receptors was detected in 40 of 44 colonic adenocarcinomas (Figure 1) . The single anal squamous cell carcinoma was negative (Figure 1 ). All of the cases which showed IL-4 receptor expression were well or moderately differentiated tumours (Table I) . Four poorly differentiated adenocarcinomas showed no labelling. All polyps (both metaplastic and neoplastic) were stained. Non-neoplastic colonic mucosa was also positively stained. The goblet cells showed mainly membranous staining compared to the cells in the crypts where the staining was both cytoplasmic and membranous.
In the tumour cells the immunostaining was homogeneous and present in both the cytoplasm and on the cell membrane and its intensity was much stronger compared to the nonneoplastic mucosa. In all cases both lymphocytes and macrophages infiltrating the tumour stroma were strongly positive for IL-4 receptor expression (Figure 1 ). Antibody EGFRI Staining for EGF receptors, using the monoclonal antibody EGFR1, was seen in 22/44 adenocarcinomas and that of the anal squamous cell carcinoma (Figure 1 ). Fourteen out of 20 colonic polyps were positively labelled (5/5 metaplastic, 4/6 villous, 5/9 tubular). Detection of staining for EGFR was detected in normal colonic epithelium in all cases whether or not the tumour was labelled for EGFR. Labelling was weak and present mainly in the basal cells of the crypts.
All but one of the adenocarcinomas which showed expression of EGFR were also positively labelled for IL-4 receptor (Table II) .
Involvement of mesenteric lymph nodes by tumour cells was seen in 25 out of 45 patients. In eighteen of these 25 cases the primary tumours were EGFR1 positive (Table III) . In only five EGFR1 positive cases could no lymph node involvement be demonstrated. Seventeen out of 22 negative cases had no lymph node involvement (Table III and Figure  2 ). Groups were compared by the chi-square test for categorical variables (X2 = 9.8, 0.001 <P<0.01, with one degree of freedom).
Discussion
In this study it has been shown that IL-4 receptors, detected by the monoclonal antibody MR6, are expressed by more than 80% of colorectal adenocarcinomas. In 60% of the IL-4R positive cases there was also coexpression of EGF receptors.
The maintenance of the expression of IL-4R in colonic tumours arising from IL-4 R( + ) mucosa agrees with studies of human squamous and adenocarcinomas of the lung (Tungekar et al., 1991) and adenocarcinomas of the breast (Mat et al., 1990) .
In lung cancers, Tungekar and colleagues (1991), demonstrated a selective distribution among tumour types suggesting that IL-4 receptors are associated with a particular differentiation pathway. Since IL-4 has inhibitory effects on some tumour cell lines, (Tepper et al., 1989) loss of IL-4 receptor may be associated with escape from a negative regulatory effect and tumour progression.
It is also known that IL-4 possesses the ability to upregulate both class I and II MHC gene expression in a variety of macrophage cell types (Stuart et al., 1988 (CACO-2) demonstrated the presence of EGFR on the basolateral and apical side of the monolayers (ratio 2.5/1) (Hidalgo et al., 1989) . On colorectal cancer specimens a decrease in EGF binding along the crypt-villous axis was also seen suggesting a loss of receptors with increasing cell differentiation (Gallo-Payet & Hugon, 1985) . Recent studies (Coffey et al., 1986; Hanauste et al., 1987) in human colon carcinoma cell lines have confirmed that malignant cells secrete several growth factors, including TGF-a/EGF, TGF-P, suggesting that these molecules may function in an autocrine fashion (Sporn & Todaro, 1980) playing a contributory role in regulating cell growth. It was also shown that a monoclonal antibody against TGF-x/EGF receptor can suppress in vitro tumour growth of a colon carcinoma cell line (Rodeck et al., 1987) .
Expression by both normal colon and neoplastic cells of high affinity EGF receptors was confirmed by immunoprecipitation (Murthy et al., 1989; Anzano et al., 1989) . However, expression of these receptors was not a constant property of malignant cells and failure of receptor detection or down-regulation has been described in other studies (Coffey et al., 1987; Rothbauer et al., 1989) .
Our results show that expression of EGFR correlates strongly with tumour progression. Since the latter is related to prognosis, EGFR1 positivity might be a reliable indicator of tumour behaviour in colon cancers.
Similar observations have been made in a variety of tumours such as lung, breast, bladder, ovary and cervix (Liberman et al., 1984; Berger et al., 1987; Gullick et al., 1986; Veale et al., 1989; Perez et al., 1984) . For breast and bladder carcinomas a strong correlation has been shown with pathological stage, relapse and survival (Neal et al., 1989; Harris et al., 1988; Nicholson et al., 1989; Sainsburry et al., 1987) .
Overall accumulated data provide evidence that overproduction of a positive growth factor (TGF-a/EGF), with simultaneous lack of responsiveness to a negative one (such as TGF-P) could influence and upregulate the proliferation of colon carcinoma cells. Although such an influence may be a necessary prerequisite, growth regulatory mechanisms other than those mediated through TGF-a/EGF may also play an important role in colon cell growth (Lane & Benchimol, 1990; Rodrigues et al., 1990; Vogelstein et al., 1988; Harris, 1990) .
